A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

NCT04908202 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

670

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

DRUG: Deucravacitinib
OTHER: Placebo

Sponsor

Bristol-Myers Squibb